AMLo Biosciences
Newcastle upon Tyne, GB · 8 known investors
Find your way into AMLo Biosciences
AMLo Biosciences develops prognostic and companion diagnostic tests for cancer patients, initially focusing on melanoma and oropharyngeal squamous cell carcinoma. The company translates cancer biomarker research into tests designed to stratify patient risk and optimize treatment allocation.
Founders & leadership
PL
Penny LovatinChief Scientific Officer
Investors · 8
Conduit ConnectLondon
Future Planet CapitalreportedLondon
Milltrust International GroupreportedLondon · $2.5M
Northstar Venturesreported · 2 sourcesNewcastle upon Tyne · $38.1K – $1.3M
Also in the syndicate · 4
Ascension's Life FundConduit's EIS Impact FundEsperanteFuture Planet Capital's BIF Opportunities Fund
Companies House · registry record
View on Companies House ↗Insolvency historyConfirmation statement overdue
- Registered name
- AMLO BIOSCIENCES LIMITED
- Company number
- 11004534
- Status
- Administration
- Company type
- Private limited company
- Incorporated
- 10 Oct 2017
- Registered office
- C/O GRANT THORNTON UK ADVISORY & TAX LLP, 11th Floor Landmark St Peters Square Oxford Street, Manchester, M1 4PB
- Nature of business (SIC)
- 71200 — Technical testing and analysis
- Accounts
- last made up to 30 Nov 2024 · next due 31 Aug 2026
- Confirmation statement
- last made up to 9 Oct 2024 · next due 23 Oct 2025
Current officers · 5
- Marie Beagley Labus — director, appointed 5 Dec 2017
- Penny Emma Lovat — director, appointed 5 Dec 2017
- David Lawrence Macdonald — director, appointed 1 Jun 2021
- Vanessa Jane Meaney — director, appointed 1 Mar 2021
- Sandy Blackadder Primrose — director, appointed 24 Nov 2020
Source: Companies House public register · retrieved 7 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does AMLo Biosciences do?
- AMLo Biosciences develops prognostic and companion diagnostic tests for cancer patients, initially focusing on melanoma and oropharyngeal squamous cell carcinoma. The company translates cancer biomarker research into tests designed to stratify patient risk and optimize treatment allocation.
- Who are AMLo Biosciences's investors?
- AMLo Biosciences's investors include Conduit Connect, Future Planet Capital, Milltrust International Group, Northstar Ventures.
- Where is AMLo Biosciences headquartered?
- AMLo Biosciences is headquartered in Newcastle upon Tyne, GB.